FDA Accepts Eisai’s Submitting of a Supplemental Biologics License Software and Grants Precedence Overview for Conventional Approval of LEQEMBI (lecanemab-irmb) for
Confirmatory Section 3 Readability AD knowledge to be evaluated by FDA in figuring out whether or not to transform accelerated approval of LEQEMBI to a standard approval Precedence Overview accelerates…